High-Fat, High-Protein, Carbohydrate-Restricted Dietary Interventions in Pompe Disease: A Case Series with Long-Term Follow-Up
Annals of Nutrition and Metabolism · 22.09.2026
DOI: 10.1159/anm/abmag008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Nutrition and Metabolism, online erschienen am 22.09.2026. Verfasst von Pelin Teke Kisa und 20 weiteren Autor:innen. Die Arbeit nennt 50 Literaturangaben.
Abstract (Originalsprache)
Introduction
Pompe disease (PD) is a lysosomal storage disorder characterized by progressive glycogen accumulation leading to cardiomyopathy and motor decline. Despite the survival benefits of enzyme replacement therapy (ERT), the long-term clinical course is often complicated by persistent skeletal muscle pathology, necessitating effective adjunctive interventions. This study aimed to evaluate the clinical utility of a high-fat, high-protein, carbohydrate-restricted dietary intervention in patients with PD.
Methods
Data collected included the initial date and duration of dietary treatment, total caloric intake, macronutrient distribution, the ratio of fat to carbohydrate plus protein, and any reported adverse effects, such as weight loss and micronutrient deficiencies.
Results
Twelve patients (7 infantile-onset PD [IOPD], 5 late-onset PD [LOPD]; median diet initiation age: 14 months for IOPD, 52 months for LOPD) maintained individualized carbohydrate-restricted, high-fat dietary therapies for >3 months, with a median follow-up duration of 23.5 (range, 3–48) months. Dietary protocols ranged from classic ketogenic diet to modified Atkins and low-carbohydrate high-fat regimens, providing 54–82% of total daily energy from fat alongside a high absolute protein intake (1.7–4.0 g/kg/day) to prevent muscle catabolism. All patients received concurrent ERT, except one LOPD patient managed exclusively with dietary therapy. The median duration of diet was 23.5 (3–48) months. Stabilization or mild-to-moderate improvements in motor function, proximal muscle strength, and physical endurance (e.g., 6-min walk test distance) were achieved across follow-up. The dietary interventions were well tolerated with no serious diet-related adverse events. A significant reduction in creatine kinase levels was observed between baseline and the third month of the diet (p = 0.015). No serious adverse effects were observed.
Conclusion
These real-world findings suggest that high-fat, high-protein, carbohydrate-restricted dietary approaches may serve as feasible adjunctive therapies in the management of PD. Further prospective and controlled studies are warranted to clarify their long-term efficacy, safety, and metabolic impact.
Zitieren
APA
Teke Kisa, P., Dogan, B. B., Zubarioglu, T., Apaydin, I., Er, E., Balci, M. C., Uzun Dincturk, D., Bilen, M., Demirdoken, E. D., Akisin, Z., Uygur, E., Erkmen, S., Hacioglu, I., Topuz, H. S., Cubukcu, D., Guzel, O., Kiykim, E., Zeybek, A. C. A., Gokcay, G., …, & Arslan, N. (2026). High-Fat, High-Protein, Carbohydrate-Restricted Dietary Interventions in Pompe Disease: A Case Series with Long-Term Follow-Up. Annals of Nutrition and Metabolism. https://doi.org/10.1159/anm/abmag008
Vancouver
Teke Kisa P, Dogan BB, Zubarioglu T, Apaydin I, Er E, Balci MC, et al. High-Fat, High-Protein, Carbohydrate-Restricted Dietary Interventions in Pompe Disease: A Case Series with Long-Term Follow-Up. Annals of Nutrition and Metabolism. 2026. doi:10.1159/anm/abmag008
BibTeX
@article{TekeKisa2026,
author = {Teke Kisa, Pelin and Dogan, Beyza Belde and Zubarioglu, Tanyel and Apaydin, Ilayda and Er, Esra and Balci, Mehmet Cihan and Uzun Dincturk, Duygu and Bilen, Merve and Demirdoken, Emine Didem and Akisin, Zeynep and Uygur, Esma and Erkmen, Semra and Hacioglu, Ilknur and Topuz, Hanim Seyma and Cubukcu, Duygu and Guzel, Orkide and Kiykim, Ertugrul and Zeybek, Ayse Cigdem Aktuglu and Gokcay, Gulden and Önal, Hasan and Arslan, Nur},
title = {High-Fat, High-Protein, Carbohydrate-Restricted Dietary Interventions in Pompe Disease: A Case Series with Long-Term Follow-Up},
journal = {Annals of Nutrition and Metabolism},
year = {2026},
doi = {10.1159/anm/abmag008}
}
EUVIMED